Co-founder & Chief Executive Officer
François-Henri holds an MSc in Management from ESSEC Business School. Prior to founding nova, he spent 4 years with the investment bank Lehman Brothers in London and Tokyo where he has developed an expertise in financial engineering, deal structuring & execution. François-Henri has participated in securitization deals across a wide range of assets representing total completed financings in excess of US$ 500 million in Europe and Asia.
As Novadiscovery’s cofounder and CEO since 2010, François-Henri has honed a variety of skills ranging from corporate structuring to business development and people management.
Co-founder & Chief Technology Officer
Frederic graduated from Ecole Polytechnique in Paris with an Applied Mathematics Master in Probabilities and Finance.
He then worked for 12 years in financial market modelling and quantitative trading across London, Tokyo and Singapore, most recently as Managing Director for Standard Chartered Bank. During that time Frederic has managed teams of traders, quants, computer scientists and IT engineers to build large yet efficient and scalable analytics and trading frameworks.
His focus is on simulated outcome based reasoning and decision making where model hypothesis are always tested through the prism of scenarios and large scale simulations.
Co-founder & Chairman of the Scientific Advisory Board
Jean-Pierre is a cardiologist by training. He was until recently an Emeritus Professor of Clinical Pharmacology at the University of Claude Bernard Lyon 1, and has been a Scientific Director at the French Institute for Health and Medical Research (Inserm), advisor to the General Surgeon and is still a member of a number of scientific societies in Europe and the United States.
VP of Medicine
Marc is a professor of Neurology at the Grenoble Alpes University. He was the founder and director of the INSERM/DGOS Clinical Research Center (CIC/GCRC) at the University hospital. He served at the regional ARH level and was the national coordinator to improve stroke care organization in France at the Ministry of Health. He has been a member of various scientific international editorial boards and is also in charge of scientific publications at Nova.
Tero is the CEO and Board Member of BC Platforms, a company specialized in bioinformatics, genome data management and data science located in Finland. BC Platforms has built a technology platform to answer ground-breaking research questions in next-generation sequencing and genome-wide association studies.
Prior to joining BC Platforms, Tero was the CEO of Aava Group from, one of the largest healthcare service providers in North Europe (2010 to 2012). Prior to that, Terro was the CEO of Mawell Ltd from 2001 to 2011. Tero is also a board member of several companies and nonprofit organisations in the healthcare industry. Tero graduated from University of Oulu Finland with a Master in Economics.
Tanja is the CEO of Debiopharm Innovation Fund, the strategic investment fund of Debiopharm located in Lausanne, Switzerland. With €150M under management, the fund invests in digital health companies that improve patient journey and drug development in oncology and infectious disease areas.
Prior to joining Debiopharm Tanja was the Managing Partner of Innomedica Ltd, a strategy and transaction consulting company where she worked on various projects with more than 80 life science and healthcare companies globally over 20 years. Tanja graduated from the Aalto University in Helsinki (Formerly the Helsinki University of Technology) with a Master in Applied Microbiology and Biochemistry.
Philippe is the CEO of Genelpis since its inception in 2019. He is also a venture partner with the Digital Health venture team of LBO France, which he joined in early 2018 after a distinguished career in healthcare venture capital in the US. He started his business career in 1987 in the pharmaceutical industry, with Sandoz Pharmaceutical and joined in 1993 The Boston Consulting Group as a Manager.
He has made numerous marquis name investments in the healthcare sector over the years (such as Sapient Health Network, ePocrates, Spotfire, Truveris, NxStage Medical, Cephalon, Auxillium Pharmaceuticals) as part of his broader investments activities, first at The Sprout group which he joined in 1995, and then with New Leaf Venture Partners. In his role of Managing Director he led the spin-off of NLV from Sprout in 2005 and then the fundraising effort of 4 funds totaling over $1billion. Philippe earned an MDPhD degree from University Paris V and an MBA from Columbia University. He is currently a board member of several private companies in France and the US.
Cédric is a member of the executive committee of the Debiopharm group. Prior to joining the group, Cédric acquired a solid experience with European banking industry leading international projects in regulation, fiscal law and investment solutions. In 2013, Cédric became a board member of the Fondation Philanthropique Next with active projects in education, social development and ecology worldwide.
In 2016, he joined the advisory board of the Debiopharm Chair for Family Philanthropy at IMD business school. Cédric completed his academic education with a postgraduate degree from SKEMA business school Competitive Intelligence faculty, a MSc from Université Lyon II Political economy faculty, Swiss Federal Institute of Technology Department of Technology Management, followed by IMD Business School’s MBA.